- 1 Quantifying the impact of norovirus transmission in the community on acute
- 2 kidney injury hospitalisations in England: a mathematical modelling study
- 3
- 4 **Authors:**^{1*}Hikaru Bolt, ¹Pratik Gupte, ²Amy Douglas, ^{1*}Frank G. Sandmann, ¹Laurie Tomlinson,
- 5 ¹Rosalind Eggo

67 Affiliations:

- 8 1. London School of Hygiene and Tropical Medicine, *Present address: Robert Koch Institute
- 9 2. Gastrointestinal Infections, Food Safety and One Health Division, UK Health Security Agency,
- 10 London, UK
- 11
- 12 *Corresponding author:
- 13 Email: Hikaru.bolt@lshtm.ac.uk

14 Abstract

15 Norovirus is one of the most common gastrointestinal pathogens and causes substantial

16 morbidity and mortality worldwide. A serious consequence can be acute kidney injury (AKI),

17 characterised by a rapid deterioration of kidney function. A quarter of all inpatients have AKI,

18 which is associated with an increased risk of mortality. This study aimed to quantify the

19 contribution of norovirus community transmission to AKI hospitalisations in England and its

- 20 attributable cost.
- 21

We developed an age-structured deterministic compartmental dynamic transmission model for norovirus. We used a Bayesian approach to fit the model to multiple electronic health data

sources, including hospitalisations and primary care records for AKI and gastroenteritis, as well

as laboratory-confirmed norovirus surveillance data in England, from 2013-2019. We used

- 26 Markov Chain Monte Carlo to estimate the effect of norovirus incidence on community-acquired
- AKI hospitalisations. We estimate 25.4% (95% Crl: 17.9-36.3%) of norovirus infections in people

aged 65 years and above were linked to community-acquired AKI hospitalisations, amounting to

29 793,229 (95% Crl: 557,125-1,130,593) hospitalisations between 2013-2019. This represents

30 16.3% (95% Crl: 11.4-23.2%) of community acquired AKI hospitalisations in people aged 65

31 years and above over this period. The economic healthcare cost associated with norovirus-

32 linked AKI admissions was estimated to be on average £343 million annually.

33

34 Gastroenteritis has previously been identified as an important risk factor for AKI in vulnerable

35 patients. Our results suggest norovirus incidence in the community plays an important role in

36 driving AKI hospitalisations in individuals aged 65 years and above. This is the first population-

level estimate of the prevalence of norovirus infections linked to hospitalisations for AKI, and the
 comparable seasonal patterns between the two. This presents a substantial economic burden

39 on the healthcare system and AKI hospitalisation should be an important consideration when

- 40 evaluating future norovirus vaccines.
- 41
- 42 43 44

45

47 Introduction

48

49 Norovirus is a viral gastrointestinal infection that is the most commonly reported cause of acute 50 gastroenteritis in the UK, estimated to cause 3.7 million cases per year (1). While often self-51 limiting, with symptoms lasting 2-3 days, disease can be severe in children, the elderly, and 52 people with impaired immune function (2). The majority of norovirus transmission is thought to 53 occur as person-to-person transmission in the community with an important burden in settings 54 such as schools, care homes, and hospitals (3). Norovirus has a low infectious dose and is a 55 genetically diverse virus making control efforts challenging (2,4,5). In healthcare settings like 56 hospitals, outbreaks of norovirus cause major disruptions due to prolonging admissions and the 57 implementation of control measures reducing bed availability during peak winter months (3,6,7). 58 Norovirus incidence demonstrates a clear seasonality with regular peaks in winter driven by a 59 complex interplay between population immunity, environmental factors, and host-behavioural 60 factors (8,9).

61

62 Through dehydration from vomiting and diarrhoea, a serious consequence of norovirus infection

63 can be acute kidney injury (AKI). AKI is characterised by a rapid deterioration of kidney function

undermining metabolic, electrolyte, and fluid homeostasis (10). In some settings, 20-25% of all
 patients admitted to hospital are diagnosed with AKI (10,11). It is associated with prolonged

66 admissions and a 4-16-fold increase in the odds of death (11). In the UK, it is estimated that AKI

67 inpatient care and longer term impacts cost £1.02 billion annually, equivalent to 1% of the NHS

68 budget in 2011 (12). Associated risk factors for AKI include older age, chronic kidney disease,

69 hypertension, diabetes, heart failure, drug toxicity, and infection (10). This diverse range of

70 aetiologies poses challenges in targeting mechanisms to reduce the burden of AKI as a global

- 71 public health issue.
- 72

73 Hospital admissions for AKI demonstrate a seasonal pattern with winter increases, suggesting 74 infection as an important contributor of AKI burden (13–15), and a substantially increased risk 75 after gastroenteritis compared to other infections (16). Therefore, we hypothesised that 76 increases in gastrointestinal viruses, in particular norovirus, are a driver of AKI trends over time 77 in the UK. Therefore, we sought to quantify the contribution of community norovirus to AKI 78 hospitalisations, and its attributable cost. We fit a mathematical model of norovirus transmission 79 to AKI hospitalisation data and use Bayesian inference to estimate the contribution. With a 80 number of vaccine candidates for norovirus in development (17), this study presents new 81 insights that will serve to illustrate further aspects on the potential benefits of introducing

- 82 norovirus vaccination in England.
- 83 Methods

84 Transmission Model

85 To model norovirus transmission, we developed an adapted deterministic Susceptible (S),

86 Exposed (E), Infected (I), Recovered (R) model from previously published studies (18–20). The

- 87 model includes two infected compartments; symptomatic (I_s) and asymptomatic (I_a) (Figure 1).
- The model is age stratified into four age groups: 0-4; 5-14; 15-64; 65+ years. This age
- 89 stratification is to reflect young children (0-4 years) having the highest estimated incidence of
- 90 norovirus, and older adults (65+ years) who are most vulnerable to severe disease (1,19,20).
- 91



92 93

Figure 1: Compartmental model diagram with the following classes: S, susceptible; E, exposed; Ia, infectious
 asymptomatic; Is, infectious symptomatic; R, recovered. Arrows denote becoming infected, moving through the
 infection and recovery process, and waning of immunity. Force of infection is denoted by the dashed lines. Births,
 deaths, and ageing are included in the model but not depicted in the diagram.

98

99 Susceptible individuals are infected at rate λ into the Exposed compartment. Exposed

- 100 individuals have an incubation period of μ then progress to be Infected-symptomatic (I_s) or
- 101 Infected-asymptomatic (I_a). To capture heterogeneous and assortative contact patterns between
- age-groups, denoted c_{ij}, contact matrix data in the UK from the POLYMOD survey were
- 103 extracted using the R package social mixr (21,22). The proportion symptomatic is σ , and the
- 104 proportion asymptomatic 1-σ. Symptomatic individuals progress into the asymptomatic
- 105 compartment at a rate of ψ , representing the rate of loss of symptoms. Asymptomatic
- individuals then progress into the Recovered compartment at a rate of γ representing the rate ofrecovery.
- 107 r€ 108
- 109 In the recovered compartment, individuals are immune and then return to the Susceptible
- 110 compartment at a rate of ω . However, to reflect that during the period of immunity, individuals
- 111 can be re-infected but not have disease, the same force of infection applied to susceptible
- 112 individuals was applied to the recovered compartment. The full model equations, details on the
- force of infection and seasonality are in Supplement S1.
- 114

115 Model fitting overview

- 116
- 117 We fit our model to various sources of data which include: UK Health Security Agency's Second
- 118 Generation Surveillance System (SGSS), the second longitudinal study of infectious intestinal
- diseases in the UK (IID2), the Clinical Practice Research Datalink (CPRD) Aurum, and Hospital
- 120 Episode Statistics (HES). Information about each data source is outlined in Supplement S2. Use
- 121 of CPRD/HES was approved in 2023 (protocol 23_003034).
- 122

124 surveillance pyramid and as a result, capture different norovirus dynamics across the age 125 groups (Figure 2). For example, norovirus dynamics are more likely to be captured in GP data in 126 younger age groups; whereas in older age groups norovirus dynamics are more likely captured 127 in hospitalisation data. This assumption therefore underpins our fitting approach: in age groups 128 0-4 and 5-14, we fit our model to medically attended gastroenteritis captured by primary care 129 data. In the 65+ age group we fit to gastroenteritis and acute kidney injury hospitalisation data. 130 In the 15-64 age group, norovirus dynamics are poorly captured in GP and hospitalisation data, 131 therefore we did not fit to either sources. All age groups were fitted to the surveillance data and 132 community incidence estimates generated by IID2 (23). 133 134 We defined a GP attendance for gastroenteritis where there was a recorded pathogen code 135 (positive test for norovirus) or a diagnosis code (e.g. gastroenteritis) (Supplement S7.3). 136 Symptom codes (e.g. diarrhoea and vomiting only) were not included as they were non-specific. 137 138 We defined community-acquired hospitalisations as an AKI code recorded in any position 139 (primary, secondary, tertiary, etc.) in an episode within three days of admission, and refer to this 140 definition as 'AKI hospitalisation' subsequently. We defined gastroenteritis hospitalisation as a

We operate under the assumption that each source represents distinct segments of the

relevant ICD-10 code in any position in HES, at any time during an admission.

142

123

143 We fit the model to data between 2013-2019, in order to target a period after the introduction of

144 the rotavirus vaccine in order to minimise the contribution of a major causative agent for

145 gastroenteritis. Similarly, we end the observation period in 2019 in order to exclude the period of

the COVID-19 pandemic, where norovirus dynamics were disrupted and SARS-CoV-2 was a

147 major causative agent for AKI during that period.



Figure 2: Schematic of the surveillance pyramid stratified by age. Each source of data captures different segments of the pyramid. We assumed that norovirus dynamics vary across age groups, meaning certain data sources more accurately reflect these dynamics in specific age groups. Within each age group, we label the data source used to fit the model. SGSS, Second Generation Surveillance System; CPRD Aurum, Clinical Practice Research Datalink Aurum; IID2, Longitudinal study of infectious intestinal disease in the UK; HES, Hospital Episode Statistics.

173 Observation model

174 Observation model for GP attendance

175

We developed an observation model to link the modelled incidence of norovirus infections to GP attendances for gastroenteritis in age groups 0-4 and 5-14. In order to capture secular trends in the data parsimoniously, we applied a B-spline function with three knots to the modelled incidence data. The output is multiplied by a parameter to scale the modelled output to

- 180 observed data of GP attendance for all-cause gastroenteritis.
- 181 182
 - 2 Observation model for hospitalisations
- 183

184 We developed an observation model to link the modelled incidence of norovirus infections to

- hospitalisations with gastroenteritis and AKI, in people 65 years old and above. Unlike the GP
 attendance model, this approach assumes that the seasonal patterns in AKI data are partly due
- 187 to norovirus. We estimate a key parameter of the proportion of norovirus infections linked to AKI

- 188 hospitalisations, which scales the amplitude of the observation model to fit the observed AKI
- data. Through Bayesian inference, we estimate the parameter value that best matches the
- 190 observed AKI seasonality. To account for other AKI causes, we add the sinusoidal changes in
- 191 norovirus linked AKI hospitalisation data to a cubic spline representing long-term trends. A step-
- by-step explanation is outlined in Supplement S3.
- 193

194 Bayesian inference

195

We fitted the model to the different datasets and age groups using a Poisson likelihood. The log likelihood of each data source was added together to give an overall log likelihood (Supplement S3.4). To estimate the posterior distribution of the parameters giving the best fit between the model and the different data sources, we used an adaptive Markov Chain Monte Carlo (MCMC) with the Metropolis-Hastings algorithm. We run five chains of 500,000 iterations, discarding the first 50,000 to have a more representative distribution of the posteriors being estimated (burn in). We also thinned the chain by 50 in order to reduce autocorrelation in the samples (thinning).

- In the AKI hospitalisation data, there were periods of increased hospitalisations in summer
 months strongly associated with heat waves. Therefore, we collected data from the UK
 meteorological office on time periods where heat waves were declared. We excluded AKI
- hospitalisation data as part of the likelihood calculation during these weeks in order to minimise spuriously fitting parameters to data unlikely associated with norovirus dynamics.
- 209

210 Cost analysis

211

212 To estimate the economic cost of norovirus linked AKI hospitalisations we collated the reference

costs for acute kidney injury (LA07) reported by the National Health Service between 2013-2019

- (24,25). Costs associated with AKI vary by whether an intervention was made and the
 complication and comorbidity score, therefore we used the mean activity weighted reference
- complication and comorbidity score, therefore we used the mean activity weighted reference
 cost for each year. The mean reference cost was multiplied by the estimated number of AKI
- admissions linked to norovirus and a range of costs from the posterior distribution of the fitted
- 217 admissions linked to horowids and a range of costs from the posterior distribution of the filte 218 parameter. We assume a variable cost of 15%, meaning the cost saved if the norovirus
- attributable AKI hospitalisation was prevented during this period (26). All costs were inflated to
- 220 2021 using the NHS cost inflation index (27).

221 Sensitivity analysis

To examine the robustness of our results we conducted a number of sensitivity analyses. First, we fit the proposed model to include a broader definition of AKI hospitalisation. We also fit the model to AKI hospitalisation data including the periods associated with heatwaves.

- 225 226 **Software**
- 227

We carried out the analysis using R version 4.4. We developed an R package called *noromod* (<u>https://github.com/pratikunterwegs/noromod</u>) to execute the compartmental dynamic

230 transmission model of norovirus. Model fitting and analysis code are available at:

231 <u>https://github.com/ehr-lshtm/acute_kidney_injury_norovirus_transmission_model.</u>

232 Results

233 Descriptive analysis

234 Across six seasons (June to July) between 2013 and 2019, incidence of AKI hospitalisation in 235 65+ years old was 80 per 100,000 person years at the beginning of 2013 and rising year on 236 year to 131 per 100,000 person years at the end of 2019 (Supplement S4). We observed 237 distinct winter seasonal increases in AKI hospitalisation consistently peaking between week 52 238 and week 1. Norovirus surveillance peaks varied each between week 2 and 13. In the 239 2016/2017 season a peak was observed in week 47. GP attendance in children 0-4 and 5-14 for 240 gastroenteritis typically showed double peaks, with acute drops in attendance data in week 52: 241 typically a period defined by bank holidays and school closures in England. GP attendances for gastroenteritis nearly double each winter compared to summer incidence. Gastroenteritis 242 243 hospitalisation showed a much less pronounced winter seasonal peak compared to other

- sources of data. Peaks in gastroenteritis hospitalisation also occurred between week 2 and 13
- of each season.

246 Model fit and parameter estimates

247 In general, our model fits each source of data adequately (Figure 1 and Figure 2). For the 248 norovirus surveillance data, generally across the age groups the height and timing of the peaks 249 and troughs were captured (Figure 1). The amplitude of seasonality was captured less well in 250 the over 65-year-old surveillance data. For GP attendance for gastroenteritis and gastroenteritis 251 hospitalisation, peaks and troughs were captured by the model (Figure 2). The fit to AKI 252 hospitalisations captured troughs adequately, but the height and timing of the peaks were 253 captured less well (Figure 2 panel D). Compared to IID2 incidence rate data, our model reported 254 estimates within the bounds of the IID2 study estimates, except for the under 5 incidence, where 255 we underestimate incidence (Supplement S5.1).

256

257 The posterior for the probability of transmission between under five-year-olds was 0.19 (95%) 258 Crl: 0.18-0.22) and for the probability of transmission to (and between) over five years olds was 259 0.04 (95% Crl: 0.037-0.048) (Table 1). Duration of immunity was estimated to be 9.0 years 260 (95% CrI: 8.3-9.8). To fit the observed hospitalisations and surveillance data, we estimated that 261 approximately 1 in 15 over 65-year-olds with symptomatic norovirus infection were hospitalised, and 1 in 112 were reported to surveillance. When fitting the model to AKI hospitalisation data, 262 263 we estimated that the proportion of symptomatic norovirus infections linked to an AKI 264 hospitalisation was 0.25 (95% Crl: 0.18-0.36).



266

Figure 2: Model fit to norovirus surveillance data (SGSS), 2013-2019 stratified by age A) 0-4 years olds
B) 5–14-year-olds C) 15-64 year olds D) 65+ year olds



Figure 3: Model fit to various data sources, 2013-2019 A) gastroenteritis primary care attendance, 0–4 year-olds (CPRD) B) gastroenteritis primary care attendance, 5-14 year olds (CPRD) C) gastroenteritis
 hospital admission, 65+ year olds (HES) D) acute kidney injury hospital admission, 65+ year olds (HES).
 Red shaded area in panel D denotes AKI hospitalisations not included in likelihood calculation as periods
 of AKI related to heat waves. Grey shaded area represent alternating calendar years to aid in visualising

276 peak timings. In the 0-4-year-old gastroenteritis primary care data (Panel A), we excluded data from the

277 year 2013, as rotavirus vaccination had been introduced in the summer of 2013. Therefore, to improve

278 the specificity of the gastroenteritis attendances for norovirus, years where rotavirus were significantly

279 more active were excluded.

280

D		Provide an address	
Parameter	Median (95% Crl)	Explanation	
Proportion symptomatic	0.827 (0.691-0.896)	Proportion of individuals symptomatic	
Duration of immunity	9.01 (8.28-9.75)	Number of years individual is immune	
Probability of infection between under 5s	0.192 (0.179-0.216)	Probability of transmission in under 5s transmitting to under 5s	
Probability of infection to over 5s	0.0401 (0.0365-0.0478)	Probability of transmission transmitting to over 5s	
Seasonal amplitude term	0.0385 (0.0371-0.041)	A term forcing the amplitude of the periodicity in the contact rate	
Scaling seasonal amplitude for over 65	1.59 (1.18-2.18)	Scaling seasonal amplitude for over 65 seasonality to improve fit	
Seasonal offset term	0.0837 (0.0634-0.105)	A term forcing the timing of the periodicity in the contact rate	
Norovirus associated AKI hospitalisation in 65+	0.254 (0.179-0.363)	Proportion of symptomatic norovirus infections linked to an AKI hospitalisation in over 65s	
Norovirus associated hospitalisation in 65+	0.0685 (0.033-0.114)	Proportion of symptomatic norovirus infections linked to a gastroenteritis hospitalisation in over 65s	
Underreporting to surveillance 0-4	0.00192 (0.00181-0.00212)	Proportion of symptomatic norovirus in 0-4 year olds reported to surveillance	
Underreporting to surveillance 5-14	0.000466 (0.000421-0.000517)	Proportion of symptomatic norovirus in 5-14 year olds reported to surveillance	
Underreporting to surveillance 15-64	0.000775 (0.000717-0.000841)	Proportion of symptomatic norovirus in 15-64 year olds reported to surveillance	
Underreporting to surveillance 65+	0.00892 (0.00674-0.0119)	Proportion of symptomatic norovirus in over 65s reported to surveillance	
GP attendance for all cause gastroenteritis in under 5s	0.393 (0.374-0.434)	Reporting parameter linking symptomatic norovirus infection in under 5s to all cause gastroenteritis diagnosed in primary care	
GP attendance for all cause gastroenteritis in 5-14s	0.301 (0.276-0.331)	Reporting parameter linking symptomatic norovirus infection in 5-14s to all cause gastroenteritis diagnosed in primary care	

281

282

283 Table 1: Parameters and posterior estimates

284 Estimate of norovirus leading to acute kidney injury hospitalisations

285 Between 2013 and 2019, we estimate from our norovirus model that there were 3,117,707 (95% 286 Crl: 2,356,661 - 4,174,546) infections in people aged 65 years and above. Based on the 287 posterior estimate, 25.4% (95% Crl: 17.9-36.3%) were linked to an AKI hospitalisation. This 288 would amount to 793,229 (95% Crl: 557,125-1,130,593) norovirus linked AKI hospitalisations. 289 There were 4,874,534 AKI hospitalisations that meet the definition of community acquired. 290 Given this, we estimate that 16.3% (95% Crl: 11.4-23.2%) of community acquired AKI 291 hospitalisations in people aged 65 years and above could be attributable to norovirus infection 292 in 2013-2019. 293

294 Economic cost analysis

295

296 We estimate that between 2013-2019, between £314 - £366 million per year was associated

297 with norovirus linked AKI hospitalisations.

This amounts to £2.4 billion (CrI: £1.7 - £3.4 billion) during the observation period. Assuming the 15% variable cost, preventing norovirus in people aged 65 years and above and thus AKI hospitalisation would amount to £361 million (CrI: £254-£515 million) savings between 2013-

302 2019.

Year	Number of norovirus infections (thousands)	Number of AKI hospitalisations linked (thousands)	Mean activity weighted reference cost (£)	Annual total cost inflation adjusted (millions)
2013	412	105 (74-149)	2,600	£314 (£221-£447)
2014	466	119 (83-169)	2,690	£361 (£254-£514)
2015	474	120 (85-172)	2,700	£366 (£257-£521)
2016	430	109 (77-156)	2,610	£317 (£222-£452)
2017	439	112 (78-159)	2,660	£330 (£232-£470)
2018	453	115 (81-164)	2,830	£353 (£249-£505)
2019	445	113 (79-161)	3,000	£366 (£257-£521)
Total	3,118	793 (557-1,131)		£2,407 (£1,692-£3,430)

³⁰³

Table 2: Estimated annual costs associated with norovirus linked acute kidney injury hospitalisations.

305 Cost values inflated to 2021 using the NHS cost inflation index (27)

306 Sensitivity analysis

307 Broadening the definition of AKI did not change the posterior parameter estimates. Given that

308 our definition of community acquired AKI represents greater than 95% of AKI codes recorded,

309 we would expect our results to be robust. Furthermore, including hospitalisation counts strongly

associated with heat waves also did not change the posterior parameter estimates. While the
 likelihood is increased, these only represent 20 weeks out of 365 weeks of data fitted to,

likelihood is increased, these only represent 20 weeks out of 365 weeks of data fitted t
 therefore we would expect posterior parameter estimates to be unchanged.

313 Discussion

314

315 We developed a model of norovirus transmission in the community fitted to AKI data to estimate

the percentage of infections associated with community acquired AKI hospitalisation. We

- 317 estimate one in four norovirus infections can be linked to an AKI hospitalisation in the elderly,
- amounting to 793,229 hospitalisations between 2013-2019 that represent costs to the NHS of
- 319 £343 million annually.
- 320

321 Results in context

322

323 Literature on quantitative estimates of norovirus infections linked to AKI are limited. This is

because gastroenterological symptoms may have resolved by the time of hospital admission

325 leading to historical under recognition of this association through limited virological confirmation

and under ascertainment in hospital coding. Given this, most studies explore associations

327 between gastroenteritis and AKI. The prevalence of AKI among children in Uganda hospitalised

328 with gastroenteritis was 28%. (28) while conversely among people of all ages admitted with AKI 329 in Malawi 19.6% had gastroenteritis (29). A large Japanese study using routine data to 330 investigate the seasonality of AKI hospitalisations found that gastroenteritis was the third most 331 common diagnosis code on admission (12.8%) (14). Because our focus lies on estimating the 332 population-level contribution of norovirus to AKI hospitalisations, these studies are limited in 333 serving as comparators for our study's estimates. However, a self-controlled case series 334 analysis of patients taking anti-hypertensive drugs found that individuals were 43 times more 335 likely to experience an AKI admission following an episode of gastroenteritis than pre-infection, 336 substantially greater than with pneumonia or urinary tract infections. Given this high risk 337 observed in vulnerable individuals, our findings of a high proportion of norovirus linked AKI 338 hospitalisations among older adults are consistent in this context.

339

340 Explanations and implications

341

342 Our observation model suggests that norovirus plays an important role in the seasonality 343 observed in community acquired AKI hospitalisations. However, given the multifactorial nature 344 of AKI, other mechanisms not captured by the model are likely to play a role and may contribute 345 to the misalignment in the timing of norovirus peaks and that of AKI hospitalisations. Both other 346 infections and important AKI-associated comorbidities such as heart failure and myocardial 347 infarction also demonstrate seasonal associations (30–32). Detection of AKI may also vary 348 seasonally, which may be a plausible explanation of the consistent timing of the peaks of AKI 349 admissions.

350

351 Our estimate that 25% of norovirus infections are linked to an AKI hospitalisation in people over 352 65 shows the very substantial burden this infection places on health services. Norovirus 353 outbreak control efforts significantly contribute to winter pressures, and prolonged admissions 354 due to AKI further increases the burden on hospitals. The norovirus vaccine, which will be 355 available shortly, offers a potentially important mechanism through which to reduce the burden 356 of AKI hospitalisations, particularly in those at high risk such as the frail elderly, 357 immunosuppressed and those with chronic kidney disease. The healthcare costs associated 358 with AKI should also be an important consideration in the cost effectiveness analysis of a 359 norovirus vaccine. Previous estimates of the economic cost of norovirus on the NHS was nearly 360 £300 million annually, including foregone admissions (6). When considering the cost of 361 norovirus linked AKI hospitalisations, the economic burden of norovirus on the healthcare 362 system would be doubled.

- 363
- 364 Strengths and weaknesses
- 365

We have used several sources of robust large-scale national data to provide the first demonstration of the comparable seasonal patterns between AKI hospitalisations and norovirus incidence and modelled an estimate of the public health burden of this association. This estimate is important because of the challenges in having real world estimates, due to limited virological confirmation of norovirus and under ascertainment in hospital coding.

372 The accuracy of estimating norovirus-associated AKI hospitalisations relies on the reliability of 373 the norovirus model capturing dynamics appropriately. We estimated that the duration of 374 immunity was 9 years, which is comparable to previous estimates (18,19). We estimated the 375 probability of infection to be 0.19 per contact between under 5s, and 0.04 per contact with over 5s, both within the bounds of previous estimates (19,33). The rate of hospitalisation from 376 377 norovirus in the over 65s was higher than previous estimates (34). We estimated that 6.8% 378 (95% Crl: 3.3-11.0%) of gastroenteritis admissions in the elderly were attributable to norovirus, 379 while previous estimates were <1% in the elderly. Differences can be explained by differing periods of observation, outcomes, and statistical approaches. We estimated a surveillance 380 381 reporting ratio higher than that reported in the IID2 study. However we estimated a ratio of samples in 65+ year olds, where one would expect more to be reported to surveillance, 382 383 compared to the all age group estimate reported in IID2.

384

385 While the fitted parameters align with previously reported estimates and our model shows 386 strong quantitative evidence of fitting the data, several key assumptions underpin the approach. 387 Firstly, we use a seasonal forcing term, which assumes that norovirus seasonality is driven by 388 increased contacts during specific times of the year and that seasonal peaks occur consistently 389 each year. Although this term was estimated during the fitting process and includes uncertainty. 390 it oversimplifies the more nuanced mechanisms that may cause year-to-year variations in peak 391 timing, as observed in surveillance data. Despite many factors influencing norovirus and AKI 392 seasonality, the seasonal forcing term is an effective approach to summarising these patterns 393 without adding unnecessary complexity or minimising overfitting. Previous studies have 394 identified temperature as a driver of norovirus seasonality, suggesting it could be incorporated in 395 future model iterations to better account for year-to-year variations.

396

397 The limited data on norovirus incidence over time makes modelling community transmission 398 essential for estimating its incidence. To enhance our approach and better capture transmission 399 dynamics, we fit the model using multiple data sources, although these sources often involve non-specific diagnoses. With the hospitalisation data, we assume a proportion is attributable to 400 401 norovirus, acknowledging that our observation model may oversimplify accounting for other 402 causes of non-specific outcomes like AKI and gastroenteritis, as well as their seasonality. 403 Additionally, the degree to which our estimates of norovirus-linked AKI hospitalisations are truly 404 causal remains uncertain. While AKI aetiology is complex and multifactorial, our observation 405 model assumes a plausible causal mechanism through volume depletion.

406

407 Although our model shows a strong fit with the data both qualitatively and quantitatively, it does 408 not account for strain-specific dynamics. This limitation could affect factors like the duration of 409 immunity, the likelihood of symptomatic infection upon reinfection, and the probability of 410 infection. However, the study period from 2013 to 2019 was marked by stability in strain 411 dynamics, with the GII.4 Sydney strain being the dominant capsid type in England and globally 412 (35). Strain dynamics may become more significant in future model iterations, especially when 413 considering vaccination scenarios. This is also highlighted by the newly increased circulation of 414 GII.17 during the 2023-2024 season, without observed changes in the epidemiological burden 415 (36).

- 417 Conclusion
- 418
- 419 We demonstrate that norovirus incidence in the community plays an important role in driving
- 420 AKI hospitalisations and presents a large economic burden on the English healthcare system.
- 421 AKI hospitalisation should be an important consideration when evaluating future norovirus
- 422 vaccines.
- 423

424 Acknowledgements

425

426 We would like to acknowledge the funding support from the National Institute for Health and

427 Care Research (NIHR) Health Protection Research Unit (HPRU) in Modelling and Health

428 Economics, a partnership between UK Health Security Agency (UKHSA), Imperial College

London, and London School of Hygiene and Tropical Medicine. The views expressed in the

430 study are those of the authors and not necessarily those of the National Health Service, NIHR,

- 431 UK Department of Health or UKHSA. The views and opinions expressed herein are the authors'
- 432 own and do not necessarily state or reflect those of Robert Koch Institute (RKI). We would also

433 like to acknowledge Lesley Larkin, Kathleen O'Reilly, Juan Vesga, Dorothea Nitsch, and

434 Viyaasan Mahalingasivam for their invaluable advice.

435 References

- Harris JP, Iturriza-Gomara M, O'Brien SJ. Re-assessing the total burden of norovirus circulating in the United Kingdom population. Vaccine. 2017 Feb;35(6):853–5.
- 439
 439
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
 440
- 3. Koopmans M. Noroviruses in healthcare settings: a challenging problem. J Hosp Infect. 2009
 Dec;73(4):331–7.
- 443 4. Glass RI, Parashar UD, Estes MK. Norovirus Gastroenteritis. N Engl J Med. 2009 Oct 29;361(18):1776–85.
- 5. Hall AJ. Noroviruses: The Perfect Human Pathogens? J Infect Dis. 2012 Jun
 1;205(11):1622–4.
- 6. Sandmann FG, Shallcross L, Adams N, Allen DJ, Coen PG, Jeanes A, et al. Estimating the
 Hospital Burden of Norovirus-Associated Gastroenteritis in England and Its Opportunity
 Costs for Nonadmitted Patients. Clin Infect Dis. 2018 Aug 16;67(5):693–700.
- 450
 451
 451
 451
 451
 451
 451
 451
 451
 451
 452
 452
 451
 451
 451
 452
 452
 452
 453
 454
 454
 454
 455
 455
 455
 456
 457
 457
 457
 458
 459
 450
 450
 450
 450
 450
 451
 451
 451
 452
 452
 452
 452
 453
 454
 454
 454
 455
 455
 455
 456
 457
 457
 457
 458
 458
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
 450
- 8. Rohayem J. Norovirus seasonality and the potential impact of climate change. Clin Microbiol
 Infect. 2009 Jun;15(6):524–7.
- 455
 9. Lopman B, Armstrong B, Atchison C, Gray JJ. Host, Weather and Virological Factors Drive
 456
 457 Norovirus Epidemiology: Time-Series Analysis of Laboratory Surveillance Data in England
 457 and Wales. Pybus OG, editor. PLoS ONE. 2009 Aug 24;4(8):e6671.
- 458 10. Rewa O, Bagshaw SM. Acute kidney injury—epidemiology, outcomes and economics.
 459 Nat Rev Nephrol. 2014 Apr;10(4):193–207.
- 460 11. Wang HE, Muntner P, Chertow GM, Warnock DG. Acute Kidney Injury and Mortality in
 461 Hospitalized Patients. Am J Nephrol. 2012;35(4):349–55.
- 462 12. Kerr M, Bedford M, Matthews B, O'Donoghue D. The economic impact of acute kidney
 463 injury in England. Nephrol Dial Transplant. 2014 Jul 1;29(7):1362–8.
- Bolt H, Suffel A, Matthewman J, Sandmann F, Tomlinson L, Eggo R. Seasonality of
 acute kidney injury phenotypes in England: an unsupervised machine learning classification
 study of electronic health records. BMC Nephrol. 2023 Aug 9;24(1):234.
- 467 14. Iwagami M, Moriya H, Doi K, Yasunaga H, Isshiki R, Sato I, et al. Seasonality of acute
 468 kidney injury incidence and mortality among hospitalized patients. Nephrol Dial Transplant.
 469 2018 Aug 1;33(8):1354–62.
- 470 15. Phillips D, Young O, Holmes J, Allen LA, Roberts G, Geen J, et al. Seasonal pattern of
 471 incidence and outcome of Acute Kidney Injury: A national study of Welsh AKI electronic
 472 alerts. Int J Clin Pract. 2017;71(9):e13000.
- 473 16. Mansfield KE, Douglas IJ, Nitsch D, Thomas SL, Smeeth L, Tomlinson LA. Acute kidney
 474 injury and infections in patients taking antihypertensive drugs: a self-controlled case series
 475 analysis. Clin Epidemiol. 2018;10:187–202.
- 476 17. Lucero Y, Vidal R, O'Ryan G M. Norovirus vaccines under development. Vaccine. 2018
 477 Aug;36(36):5435–41.
- 478 18. Gaythorpe KAM, Trotter CL, Conlan AJK. Modelling norovirus transmission and
 479 vaccination. Vaccine. 2018 Sep;36(37):5565–71.
- 480 19. Simmons K, Gambhir M, Leon J, Lopman B. Duration of Immunity to Norovirus
 481 Gastroenteritis. Emerg Infect Dis. 2013 Aug;19(8):1260–7.
- 482 20. Steele MK, Remais JV, Gambhir M, Glasser JW, Handel A, Parashar UD, et al.
- Targeting pediatric versus elderly populations for norovirus vaccines: a model-based analysis
 of mass vaccination options. Epidemics. 2016 Dec;17:42–9.

485 21. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social Contacts
486 and Mixing Patterns Relevant to the Spread of Infectious Diseases. Riley S, editor. PLoS
487 Med. 2008 Mar 25;5(3):e74.

488 22. Funk S. socialmixr: Social Mixing Matrices for Infectious Disease Modelling.; [Internet].
 489 2018. Available from: https://cran.r-project.org/web/packages/socialmixr/index.html

- Tam CC, Rodrigues LC, Viviani L, Dodds JP, Evans MR, Hunter PR, et al. Longitudinal
 study of infectious intestinal disease in the UK (IID2 study): incidence in the community and
 presenting to general practice. Gut. 2012 Jan;61(1):69–77.
- 493 24. Department of Health and Social Care. NHS reference costs [Internet]. Available from:
 494 https://www.gov.uk/government/collections/nhs-reference-costs
- 495 25. NHS England and NHS Improvement. National Cost Collection for the NHS [Internet].
 496 Available from: https://www.england.nhs.uk/costing-in-the-nhs/national-cost-collection/
- 49726.Roberts RR. Distribution of Variable vs Fixed Costs of Hospital Care. JAMA. 1999 Feb49817;281(7):644.
- 499 27. Jones KC, Burns A. Unit Costs of Health and Social Care 2021 [Internet]. Personal
 500 Social Services Research Unit; 2021 [cited 2024 Aug 29]. Available from:
 501 https://kar.kent.ac.uk/id/eprint/92342
- Imani PD, Odiit A, Hingorani SR, Weiss NS, Eddy AA. Acute kidney injury and its
 association with in-hospital mortality among children with acute infections. Pediatr Nephrol.
 2013 Nov;28(11):2199–206.
- 505 29. Evans R, Hemmilä U, Craik A, Mtekateka M, Hamilton F, Kawale Z, et al.
 506 TO021PREVALENCE, AETIOLOGY AND OUTCOME FROM COMMUNITY ACQUIRED
 507 ACUTE KIDNEY INJURY (AKI) IN SUB-SAHARA AFRICA: RESULTS OF THE MALAWI AKI
 508 STUDY (MAKIST). Nephrol Dial Transplant. 2016 May;31(suppl_1):i70–i70.
- 509 30. Stewart S, McIntyre K, Capewell S, McMurray JJV. Heart failure in a cold climate. J Am 510 Coll Cardiol. 2002 Mar;39(5):760–6.
- 511 31. Yamamoto Y, Shirakabe A, Hata N, Kobayashi N, Shinada T, Tomita K, et al. Seasonal
 512 variation in patients with acute heart failure: prognostic impact of admission in the summer.
 513 Heart Vessels. 2015 Mar;30(2):193–203.
- 51432.Arntz H. Diurnal, weekly and seasonal variation of sudden death. Population-based515analysis of 24061 consecutive cases. Eur Heart J. 2000 Feb 15;21(4):315–20.
- 516 33. O'Reilly KM, Sandman F, Allen D, Jarvis CI, Gimma A, Douglas A, et al. Predicted
 517 norovirus resurgence in 2021–2022 due to the relaxation of nonpharmaceutical interventions
 518 associated with COVID-19 restrictions in England: a mathematical modeling study. BMC
 519 Med. 2021 Dec;19(1):299.
- 520 34. Verstraeten T, Jiang B, Weil JG, Lin JH. Modelling Estimates of Norovirus Disease in 521 Patients with Chronic Medical Conditions. PLOS ONE. 2016 Jul 20;11(7):e0158822.
- 52235.Public Health England. PHE National norovirus and rotavirus Report 09 April 2020 –523Week 15 report (data to week 13) [Internet]. Available from:
- 524 https://www.gov.uk/government/statistics/norovirus-and-rotavirus-summary-of-surveillance-525 2019-to-2020
- 526 36. Chhabra P, Wong S, Niendorf S, Lederer I, Vennema H, Faber M, et al. Increased
 527 circulation of GII.17 noroviruses, six European countries and the United States, 2023 to
 528 2024. Eurosurveillance [Internet]. 2024 Sep 26 [cited 2024 Sep 30];29(39). Available from:
- 529 https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.39.2400625